🇺🇸 FDA
Patent

US 11033631

Methods of treating CYP2D6 alternative metabolizers

granted A61KA61K47/60A61P

Quick answer

US patent 11033631 (Methods of treating CYP2D6 alternative metabolizers) held by Nektar Therapeutics expires Mon Jun 10 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Nektar Therapeutics
Grant date
Tue Jun 15 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 10 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61K, A61K47/60, A61P, A61P3/00, A61P43/00